Symptomatic, Aggressive, Sporadic, Unresectable, Locally
1 clinical trials · Condition
◉ Watch Symptomatic, Aggressive, Sporadic, Unresectable, Locally
| Record | Firm | Date |
|---|---|---|
| Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (NCT01945762) | Genzyme, a Sanofi Company | 2014-02-17 |
Track Symptomatic, Aggressive, Sporadic, Unresectable, Locally automatically
Every clearance here is in the API, with alerts when new ones post.